ライフサイエンスコーパス: stomatitis

1 en dexamethasone mouthwash for prevention of stomatitis).

2 atients had adverse events in the extension (stomatitis).

3 from Behcet's disease and recurrent aphthous stomatitis.

4 s are critical for the prevention of denture stomatitis.

5 ers, Behcet's disease and recurrent aphthous stomatitis.

6 d the percentage of patients without denture stomatitis.

7 mar-plantar erythrodysesthesia syndrome, and stomatitis.

8 (28% vs 15%), lymphopenia (17% vs 10%), and stomatitis (13% vs 16%).

9 on (55 [19%] of 283 vs 74 [27%] of 271), and stomatitis (138 [49%] of 284 vs 162 [59%] of 273); 60 (2

10 tinib group), rash (29 [7%] vs 12 [3%]), and stomatitis (15 [3%] vs two [<1%]).

11 e group), diarrhoea (30 [9%] vs three [2%]), stomatitis (20 [6%] vs 13 [8%]), fatigue (18 [6%] vs fiv

12 association with everolimus monotherapy were stomatitis (26 [62%] of 42) and diarrhoea (16 [38%]); an

13 in alone group (four [1%]), as was grade 3-4 stomatitis (26 [8%] vs seven [2%]).

14 t common adverse events with everolimus were stomatitis (314 [67%] of 472 patients in the everolimus

15 febrile neutropenia (44 [16%] vs ten [4%]), stomatitis (37 [13%] vs four [1%]), and fatigue (34 [12%

16 ion (50.9%), decreased appetite (45.6%), and stomatitis (45.6%).

17 Stomatitis (48 [43%] patients) and mouth ulceration (33

18 [33%]), neutropenia (66 [19%] vs 49 [14%]), stomatitis (54 [15%] vs 10 [3%]), hypokalaemia (52 [15%]

19 up were neutropenia (117 [25%] vs 35 [15%]), stomatitis (59 [13%] vs three [1%]), anaemia (46 [10%] v

20 s with LTBI had lower odds of having candida stomatitis (adjusted odds ratio (OR) = 0.68, p = 0.0035)

21 limiting toxic effects-one developed grade 3 stomatitis and fatigue and one developed arthralgia and

22 y endpoint was incidence of grade 2 or worse stomatitis by 8 weeks assessed in the full analysis set

23 influenza A, Zika, Ebola, Sindbis, vesicular stomatitis, cowpox, and vaccinia, but not murine leukemi

24 he incidences of grade 3 or 4 neurotoxicity, stomatitis, diarrhea, and neutropenia were significantly

25 Denture-associated stomatitis (DS) affects over two-thirds of denture-weare

26 Candida-associated denture stomatitis (DS) is a persistent and chronic oral infecti

27 ure-wearing patients were recruited (denture stomatitis (DS) n = 8; non-denture stomatitis (NoDS) n =

28 hataemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatraemia (eight [5%]), abd

29 hyperglycaemia (seven [17%] of 42 patients), stomatitis (four [10%]), and diarrhoea (three [7%]); tho

30 limus/bevacizumab were mucosal inflammation, stomatitis, hypophosphatemia, hyperglycemia, and hyperch

31 patients, dry skin in 39 (44%) patients, and stomatitis in 36 (40%) patients.

32 1%] vs three [1.1%] and methotrexate-related stomatitis in 48 [18.0%] vs 12 [4.5%]).

33 tially reduced the incidence and severity of stomatitis in patients receiving everolimus and exemesta

34 amethasone-based mouthwash for prevention of stomatitis in patients with breast cancer.

35 adverse events were infrequent and included stomatitis (in 18 [9%] of 202 patients in the everolimus

36 Topical steroids might reduce stomatitis incidence and severity, and the need for dose

37 lovirus-based therapies.IMPORTANCE Vesicular stomatitis Indiana virus (VSIV) is a veterinary pathogen

38 Vesicular stomatitis Indiana virus (VSIV), formerly known as vesic

39 te systems such as the rhabdovirus vesicular stomatitis Indiana virus (VSV), lentiviruses or gammaret

40 expression and protection against vesicular stomatitis Indiana virus infection compared with wild ty

41 Stomatitis is a class effect associated with the inhibit

42 Denture-associated stomatitis is a common candidal infection that may give

43 tudied the cytotoxic activity of a vesicular stomatitis/measles hybrid virus (VSV-FH), which is super

44 s receiving EC-D reported significantly more stomatitis, myalgia or arthralgia, vomiting, nausea, fat

45 uded gastrointestinal symptoms (n = 9), mild stomatitis (n = 5), and alopecia (n = 4).

46 dverse events, the most common of which were stomatitis (nine [8%]) and pneumonia (nine [8%]).

47 (denture stomatitis (DS) n = 8; non-denture stomatitis (NoDS) n = 11) and the oral bacterial microbi

48 one [2%]), pneumonitis (none vs five [9%]), stomatitis (none vs five [9%]), and hand-foot syndrome (

49 ) were upper respiratory tract infection and stomatitis of mostly grade 1 or 2 severity.

50 n a common spectrum, with recurrent aphthous stomatitis on the mild end, Behcet's disease on the seve

51 aronychia (26 [11%] in LUX-Lung 3 only), and stomatitis or mucositis (13 [5%] in LUX-Lung 6 only).

52 of 239 patients), diarrhoea (13 [5.4%]), and stomatitis or mucositis (13 [5.4%]), compared with neutr

53 OR=1.54, P=0.001), and no detectable denture stomatitis (OR=2.89, P<0.001) significantly increased af

54 enetic similarities among recurrent aphthous stomatitis, PFAPA, and Behcet's disease, placing these d

55 rt an adult case of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome,

56 Periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) i

57 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) s

58 udotyped with different envelopes (vesicular stomatitis, Rabies, Mokola and Ross River viral envelope

59 Recurrent aphthous stomatitis (RAS) is the most common disease affecting or

60 the use of ozone to treat recurrent aphthous stomatitis (RAS).

61 ical diagnoses, including recurrent aphthous stomatitis (RAS).

62 The most common adverse events included stomatitis, rash, and diarrhea.

63 which was persist for several days, aphthous stomatitis, tongued tonsillitis with moss, pharyngitis,

64 sient detection of the recombinant vesicular stomatitis vaccine virus in blood.

65 EPNs that incorporate the vesicular stomatitis viral glycoprotein can fuse with target cells

66 ltransferase-defective recombinant vesicular stomatitis virus (mtdVSV) and a DNA vaccine.

67 The recombinant vesicular stomatitis virus (rVSV) Ebola vaccine was shown to be ve

68 , we demonstrated that recombinant vesicular stomatitis virus (rVSV) expressing human NoV capsid prot

69 Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolaviru

70 clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated th

71 iculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus gly

72 Recombinant vesicular stomatitis virus (rVSV) was shown to be a highly effecti

73 ing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccine vectors

74 replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate designed

75 replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire

76 is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEB

77 Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which enc

78 mulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make them suitabl

79 plicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surface glycop

80 Vesicular stomatitis virus (VSV) (a rhabdovirus) and its variant V

81 to induce G(2)/M arrest.IMPORTANCE Vesicular stomatitis virus (VSV) (a rhabdovirus) and its variant V

82 MxA is considered antiviral toward vesicular stomatitis virus (VSV) (a rhabdovirus).

83 eplication of the (-)ssRNA viruses vesicular stomatitis virus (VSV) (Rhabdoviridae family) and Rift V

84 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancreatic ductal adenoca

85 ediate pH for two vesiculoviruses, vesicular stomatitis virus (VSV) and Chandipura virus (CHAV), whic

86 functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriomeningitis

87 proteins of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus (RABV), possess

88 protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catalyzes the t

89 The glycoproteins (G proteins) of vesicular stomatitis virus (VSV) and related rhabdoviruses (e.g.,

90 ns with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncytial Virus (

91 NA viruses with broad host ranges, vesicular stomatitis virus (VSV) and Sindbis virus (SINV), are com

92 e experimental data on the DMFE of Vesicular stomatitis virus (VSV) and Tobacco etch virus (TEV), we

93 Oncolytic viruses such as vesicular stomatitis virus (VSV) are being considered as anticance

94 have been employed here to purify vesicular stomatitis virus (VSV) as a model case, however this tec

95 specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model virus on SP-IRIS platf

96 Using vesicular stomatitis virus (VSV) as a model, we coinfected BHK cel

97 ribe such a strategy that utilizes vesicular stomatitis virus (VSV) as a vector for chimeric hemagglu

98 Vesicular stomatitis virus (VSV) assembly requires condensation of

99 Vesicular stomatitis virus (VSV) based oncolytic viruses are promi

100 te a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glyc

101 release and infection by chimeric vesicular stomatitis virus (VSV) containing the envelope proteins

102 Recombinant vesicular stomatitis virus (VSV) encoding the hemagglutinin-like e

103 VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F and H entry

104 developed a replication-competent vesicular stomatitis virus (VSV) expressing a modified form of the

105 g an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a marker of in

106 opism, we asked whether a chimeric vesicular stomatitis virus (VSV) expressing the EBOV glycoprotein

107 Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zaire glycopr

108 strated that recombinant wild-type vesicular stomatitis virus (VSV) expressing the HBV middle surface

109 pressing the SARS-CoV-1 spike, and vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike.

110 Vesicular stomatitis virus (VSV) has been extensively studied as a

111 Replication of vesicular stomatitis virus (VSV) has long served as a model for un

112 its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a systemic oncolyt

113 Vesicular stomatitis virus (VSV) has shown substantial promise, bu

114 tonomously replicating recombinant vesicular stomatitis virus (VSV) in which the glycoprotein was rep

115 na virus (VSIV), formerly known as vesicular stomatitis virus (VSV) Indiana (VSV(IND)), is a model vi

116 compassing the appendage region of vesicular stomatitis virus (VSV) Indiana serotype L protein with t

117 78 results in a robust decrease of vesicular stomatitis virus (VSV) infection and a corresponding enh

118 Vesicular stomatitis virus (VSV) infection downregulates NLRP12 ex

119 FN production in macrophages after vesicular stomatitis virus (VSV) infection, and HIPK2-deficient mi

120 ating the host IFN response during vesicular stomatitis virus (VSV) infection.

121 as IFP35) as a factor required for vesicular stomatitis virus (VSV) infection.

122 deficient macrophages to withstand vesicular stomatitis virus (VSV) infection.

123 Vesicular stomatitis virus (VSV) is a promising oncolytic virus (O

124 Vesicular stomatitis virus (VSV) is an archetypical member of Mono

125 Vesicular stomatitis virus (VSV) is the prototype for negative sen

126 s since the first structure of the vesicular stomatitis virus (VSV) L protein determined in 2015 and

127 ryomicroscopy the structure of the vesicular stomatitis virus (VSV) L protein.

128 The complex closely resembles the vesicular stomatitis virus (VSV) L-P, the one other known full-len

129 The distribution of vesicular stomatitis virus (VSV) nucleocapsids in the cytoplasm of

130 cule against infection with either vesicular stomatitis virus (VSV) or influenza was demonstrated to

131 ell-to-cell transmission of either vesicular stomatitis virus (VSV) or the retrovirus MoMLV.

132 Vesicular stomatitis virus (VSV) P is dimeric with an oligomerizat

133 Assembly of vesicular stomatitis virus (VSV) particles requires the separate t

134 Upon treatment with vesicular stomatitis virus (VSV) particles, plasmacytoid dendritic

135 , murine leukemia virus (MLV), and vesicular stomatitis virus (VSV) particles.

136 constructs were incorporated onto vesicular stomatitis virus (VSV) pseudoparticles and transduction

137 o-cell fusion assays, and chimeric vesicular stomatitis virus (VSV) recombinants expressing the RABV

138 genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable promise both a

139 spread, and only minimally affects vesicular stomatitis virus (VSV) spread, to adjacent cells in a mo

140 udy, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its natural neu

141 developed a recombinant strain of vesicular stomatitis virus (VSV) that specifically targets transfo

142 By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore and eithe

143 inhibitors in cells infected with vesicular stomatitis virus (VSV) to identify miRNAs that regulate

144 eficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutralising abili

145 osolic poly(I:C), 5'ppp-dsRNA, and vesicular stomatitis virus (VSV) triggers IFN-I expression in over

146 t utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that lacks the na

147 accine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and express in

148 Vesicular stomatitis virus (VSV) vectors that express heterologous

149 a simplified system, we generated vesicular stomatitis virus (VSV) virions pseudotyped with HSV-1 es

150 VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its G glycopro

151 s work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of Maraba vir

152 apers describe the pseudotyping of vesicular stomatitis virus (VSV) with the SARS-CoV-2 spike.

153 ral activity of interferon against vesicular stomatitis virus (VSV), a model virus that whose genome

154 Work with vesicular stomatitis virus (VSV), a prototype, supports a model of

155 We injected vesicular stomatitis virus (VSV), a transsynaptic tracer, or natur

156 t MEFs exhibit impaired control of vesicular stomatitis virus (VSV), a virus sensed by STING that can

157 A, modified vaccinia Ankara (MVA), vesicular stomatitis virus (VSV), adenovirus type 5 (Ad5), rhesus

158 s of Ebola virus, influenza virus, vesicular stomatitis virus (VSV), and measles virus in GBA knockou

159 took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothesis that t

160 ficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-compete

161 limited the cytopathic effect from Vesicular stomatitis virus (VSV), Encephalomyocarditis virus (EMCV

162 abies virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the codon-opti

163 bdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type or codon-op

164 The virus studied here, vesicular stomatitis virus (VSV), like its relative, rabies virus,

165 ithin 2-6 hours after infection by vesicular stomatitis virus (VSV), newly assembled VSV particles ar

166 on with influenza A virus (IAV) or vesicular stomatitis virus (VSV), respectively.

167 eficient MEFs, upon infection with vesicular stomatitis virus (VSV), revealed diminished IFNbeta expr

168 Here, a prototype RNA virus, vesicular stomatitis virus (VSV), was cultured for three passages

169 those of the related rhabdovirus, vesicular stomatitis virus (VSV), we demonstrate that both polymer

170 s and primary fibroblasts with the vesicular stomatitis virus (VSV), we detected DNA complementary to

171 of NNS RNA virus gene expression, vesicular stomatitis virus (VSV), we determined the importance of

172 Working with vesicular stomatitis virus (VSV), we previously showed that a pane

173 strain of the negative-sense ssRNA vesicular stomatitis virus (VSV), we show that microinjection of V

174 Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses that inclu

175 crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically

176 In this study, we developed a vesicular stomatitis virus (VSV)-based human NoV vaccine candidate

177 rrying large transgenes.IMPORTANCE Vesicular stomatitis virus (VSV)-based oncolytic viruses are promi

178 ss these limitations, we devised a vesicular stomatitis virus (VSV)-based probe to display membrane-e

179 Using a vesicular stomatitis virus (VSV)-based pseudoparticle seroneutrali

180 Here, vesicular stomatitis virus (VSV)-based pseudovirions displaying di

181 repertoire after administration of vesicular stomatitis virus (VSV)-Ebola vaccine at 3 million, 20 mi

182 One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVSV-ZEBOV, a

183 In the vesicular stomatitis virus (VSV)-induced encephalitis model, the r

184 In vesicular stomatitis virus (VSV)-infected Huh7 cells, the nucleoca

185 case (RLH) signaling contribute to vesicular stomatitis virus (VSV)-mediated triggering of type I IFN

186 d, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon beta (IFNbeta)-

187 ls that are resistant to oncolytic vesicular stomatitis virus (VSV).

188 a virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV).

189 ma (HNSCC) lines from oncolysis by vesicular stomatitis virus (VSV).

190 l of prostate cancer infected with vesicular stomatitis virus (VSV).

191 gets for the matrix (M) protein of vesicular stomatitis virus (VSV).

192 uses comes largely from studies of vesicular stomatitis virus (VSV).

193 was observed for the IFN-sensitive vesicular stomatitis virus (VSV).

194 ns, as is observed for the related Vesicular stomatitis virus (VSV).

195 CMV); influenza A virus (IAV); and vesicular stomatitis virus (VSV).

196 ed mutagenesis of the L protein of vesicular stomatitis virus (VSV, a prototypic NNS RNA virus) to ex

197 which the transmembrane domain of vesicular stomatitis virus (VSV-TMD) promotes both initiation of f

198 Here we show that both RNA (vesicular stomatitis virus [VSV]) and DNA (cytomegalovirus [CMV])

199 y endosomes (SFV, SINV, CHIKV, and vesicular stomatitis virus [VSV]), while viruses that fuse in the

200 to infection with the RNA viruses vesicular stomatitis virus and Sendai virus and to transfection wi

201 iral infections with influenza and vesicular stomatitis virus can persist after resolution of infecti

202 endent RNA polymerase L protein of vesicular stomatitis virus catalyzes unconventional pre-mRNA cappi

203 Using a recombinant vesicular stomatitis virus containing LUJV GP as its sole attachme

204 We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona variant GP1

205 lls were infected with recombinant vesicular stomatitis virus encoding EBOV antigens.

206 nfluenza, measles, Ebola, Lassa or vesicular stomatitis virus envelope glycoproteins enabled us to st

207 glia, fibroblasts, or melanocytes, vesicular stomatitis virus evoked robust beta interferon (IFN-beta

208 ity in vitro against a recombinant vesicular stomatitis virus expressing MACV GPC (VSV-MACV) as well

209 e vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-E

210 asmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavirus glycopr

211 s to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavirus glycopr

212 fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses.

213 d secretory membrane glycoprotein, vesicular stomatitis virus G (VSVG) glycoprotein, was reduced comp

214 While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it

215 ion of the Jurkat T-cell line with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-

216 s," are designed to co-encapsulate vesicular stomatitis virus G protein (VSV-G) with bioactive macrom

217 By contrast, secretory traffic of vesicular stomatitis virus G protein, recycling of internalized tr

218 th virus-like particles displaying vesicular stomatitis virus G protein, RNAdjuvant promoted the form

219 of SAMHD1 does not rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors infection in

220 havirus RNA replicon expresses the vesicular stomatitis virus glycoprotein (VSV G) as the only struct

221 rus RNA replicons that express the vesicular stomatitis virus glycoprotein (VSV G) has been described

222 Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped viruse

223 nd that augmenting fusion with the vesicular stomatitis virus glycoprotein (VSVG) increased the amoun

224 A to an exosome-anchoring protein: vesicular stomatitis virus glycoprotein (VSVG), we demonstrate tha

225 ass III fusion proteins, including vesicular stomatitis virus glycoprotein G (VSV-G) or baculovirus g

226 e (Env) glycoprotein, but not with vesicular stomatitis virus glycoprotein G (VSV-G).

227 ancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with modified gi

228 o retroviruses, as it also acts on vesicular stomatitis virus glycoproteins.

229 Vesicular stomatitis virus has been shown to bud basolaterally, an

230 iral protection against Sendai and vesicular stomatitis virus in a TLR3 and type I IFN receptor-depen

231 tion with RIG-I and with infecting vesicular stomatitis virus in Cos-7 cells.

232 ous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vector express

233 ly after Listeria monocytogenes or vesicular stomatitis virus infection but comparable cytolytic func

234 vates the IFN pathway and inhibits vesicular stomatitis virus infection by directly targeting several

235 hocytic choriomeningitis virus and vesicular stomatitis virus infection models.

236 otic triggers such as etoposide or vesicular stomatitis virus infection, but disassemble into small a

237 inhibition during influenza A and vesicular stomatitis virus infection, but not murine hepatitis vir

238 to induce apoptosis in response to vesicular stomatitis virus infection.

239 nal approach to the attenuation of vesicular stomatitis virus neurovirulence.

240 ults were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola virus glyc

241 Among vaccines, only the vesicular stomatitis virus platform has been successful in providi

242 pact on antibody neutralization of vesicular stomatitis virus pseudotyped with Ebola virus GP.

243 ke particle, and EBOV glycoprotein/vesicular stomatitis virus pseudovirion.

244 Using vesicular stomatitis virus pseudovirions bearing EBOV glycoprotein

245 red by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack native G glycop

246 hows reduced capability to control vesicular stomatitis virus replication and to induce apoptosis in

247 both glioma and melanoma, whereas vesicular stomatitis virus replication was blocked.

248 HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homotypic virus-cell fusion.

249 from La Crosse orthobunyavirus and vesicular stomatitis virus reveal insights into RNA synthesis and

250 nd 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva.

251 By in situ analyses of vesicular stomatitis virus RNA synthesis, specific activities of v

252 (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in Liberia.

253 fficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A/Hanoi/304

254 A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBO

255 rus) and heterologous (inactivated vesicular stomatitis virus) antigens and acceptable accuracy/linea

256 s involving viral vectors (such as vesicular stomatitis virus), and antisense compounds directly targ

257 rticle, we study the polymerase of vesicular stomatitis virus, a member of the rhabdoviruses, which h

258 Vesicular stomatitis virus, a single-stranded RNA virus, triggers

259 virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, and measles

260 luding encephalomyocarditis virus, vesicular stomatitis virus, and influenza virus, in susceptible ce

261 the L protein from a rhabdovirus, vesicular stomatitis virus, at 1.8-A resolution.

262 irus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus type 1, o

263 pha interferon (IFN-alpha) against vesicular stomatitis virus, Indiana serotype (VSV(IND)), a prototy

264 n entry inhibitor for JUNV and for vesicular stomatitis virus, lymphocytic choriomeningitis virus, an

265 on of dsRNA in cells infected with vesicular stomatitis virus, measles virus, influenza A virus, and

266 enges with Listeria monocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispensable in

267 an UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, or adenovirus.

268 c viruses, including rabies virus, vesicular stomatitis virus, Semliki Forest virus, and herpes simpl

269 with poliovirus and then moving to vesicular stomatitis virus, where he discovered a virion RNA polym

270 recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a su

271 ing units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the

272 used a vesicular stomatitis virus-based probe to isolate B cells expressi

273 recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glyc

274 n phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycop

275 A live, recombinant vesicular stomatitis virus-based vaccine has been deployed in outb

276 The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-ZEBOV is cu

277 e results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly confer pro

278 Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the m

279 expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine

280 immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein

281 valuated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein

282 istency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein

283 expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine (rVSV-ZEBOV)

284 cked up the use of the recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine in the recomm

285 ed after intranasal challenge with vesicular stomatitis virus.

286 able to neutralize RPV-pseudotyped vesicular stomatitis virus.

287 HIV-1, human metapneumovirus, and vesicular stomatitis virus.

288 beta, in protection from oncolytic vesicular stomatitis virus.

289 6N2, and H11N9 IAV strains but not vesicular stomatitis virus.

290 e from neuropathogenesis caused by vesicular stomatitis virus.

291 These trials used vesicular-stomatitis-virus-G protein (VSV-G)-LVs at high doses com

292 Recombinant vesicular stomatitis viruses (rVSV) expressing foreign glycoprotei

293 RhIVs are based on vesicular stomatitis viruses (VSV), but viral entry is mediated by

294 Chimeric vesicular stomatitis viruses with the EBOV glycoprotein substitute

295 ity assays with BCoV-S-pseudotyped vesicular stomatitis viruses.

296 AV), measles (MV), Sendai (SV), or vesicular stomatitis (VSV) virus.

297 y 8 weeks, the incidence of grade 2 or worse stomatitis was two (2%) of 85 patients (95% CI 0.29-8.24

298 e most common were rash, hyperglycaemia, and stomatitis, which each affected two [2%] patients).

299 afatinib (39 [10%] vs nine [2%]), of grade 3 stomatitis with afatinib (16 [4%] vs none), and of grade

300 neutropenia, impaired wound healing, severe stomatitis with oral stenosis, and death.